1. Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal.
- Author
-
Pavlovsky C, Vasconcelos Cordoba B, Sanchez MB, Moiraghi B, Varela A, Custidiano R, Fernandez I, Freitas MJ, Ventriglia MV, Bendek G, Mariano R, Mela Osorio MJ, Pavlovsky MA, de Labanca AG, Foncuberta C, Giere I, Vera M, Juni M, Mordoh J, Sanchez Avalos JC, Cueto G, Miranda S, Levy EM, and Bianchini M
- Subjects
- Humans, Protein Kinase Inhibitors, Biomarkers, Remission Induction, Treatment Outcome, Interleukin-6, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
- Abstract
Treatment-free remission (TFR) in chronic myeloid leukemia (CML) is safe under adequate molecular monitoring, but questions remain regarding which factors may be considered predictive for TFR. Argentina Stop Trial (AST) is a multicenter TFR trial showing that 65% of patients sustain molecular remission, and the prior time in deep molecular response (DMR) was associated with successful TFR. Luminex technology was used to characterize cytokines in plasma samples. Using machine learning algorithms, MCP-1 and IL-6 were identified as novel biomarkers and MCP-1
low /IL-6low patients showed eightfold higher risk of relapse. These findings support the feasibility of TFR for patients in DMR and MCP-1/IL-6 plasma levels are strong predictive biomarkers., (© 2023. The Author(s).)- Published
- 2023
- Full Text
- View/download PDF